Clinical Trial Update: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nimotuzumab plus NALIRIFOX for locally advanced pancreatic cancer is listed as ACTIVE_NOT_RECRUITING; sponsor is Peking Union Medical C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Locally Advanced Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING